Skip to main content
Clinical Trials/NCT04355169
NCT04355169TerminatedPhase 2

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine in Patients Undergoing Surgeries That Include a Bowel Resection or Bowel Transection

Shionogi8 sites in 1 country2 target enrollmentStarted: November 6, 2020Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Terminated
Sponsor
Enrollment
2
Locations
8
Primary Endpoint
Time From the End of Surgery to Time to First Toleration of Solid Food and First Bowel Movement (GI2)

Study Overview

Brief Summary

The objective of this study is to compare the efficacy of naldemedine versus placebo and to assess its effect on the time to gastrointestinal (GI) recovery following surgeries that include bowel resection and bowel transection.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Scheduled to undergo 1 of the following procedures via open (nonlaparoscopic) surgery under general anesthesia:
  • partial small or large bowel resection with primary anastomosis
  • radical cystectomy requiring bowel transection with primary anastomosis
  • Planned to be managed postoperatively with an enhanced recovery protocol, which, at a minimum, includes all of the following elements:
  • early removal of the nasogastric tube, which is defined as removal of the nasogastric tube at the end of surgery
  • early ambulation, which is defined as ambulation on Day 1
  • early diet advancement on Day 1
  • Planned to receive primary postoperative pain management with opioid analgesia administered by any route.
  • American Society of Anesthesiologists (ASA) Physical Status Score of I, II, or III (a normal healthy participant, a participant with mild systemic disease, and a participant with systemic disease, respectively).

Exclusion Criteria

  • Scheduled to undergo a total colectomy or any procedure that results in a colostomy or ileostomy.
  • Scheduled for endoscopic or laparoscopic surgery.
  • Complete bowel obstruction.
  • Complicated inflammatory bowel disease (such as ulcerative colitis or Crohn's disease).
  • More than 2 major abdominal surgery (for example, gastrectomy, gastric bypass, gastric sleeve, lap banding, pancreatic resection, hepatectomy, intestinal transplant).
  • More than 3 doses of an opioid (regardless of the route of administration) during the 7 days prior to surgery.
  • Pregnancy or lactation.
  • Presence of peritoneal catheter (for example, for dialysis or chemotherapy).

Arms & Interventions

Naldemedine 1.25 mg

Experimental

Participants will receive 1.25 milligrams (mg) naldemedine twice daily (BID) beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.

Intervention: Naldemedine (Drug)

Naldemedine 2.5 mg

Experimental

Participants will receive 2.5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.

Intervention: Naldemedine (Drug)

Naldemedine 5 mg

Experimental

Participants will receive 5 mg naldemedine BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.

Intervention: Naldemedine (Drug)

Placebo

Placebo Comparator

Participants will receive matching placebo BID beginning on the day of surgery (Day 1) and for up to a maximum of 10 days post-surgery.

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

Time From the End of Surgery to Time to First Toleration of Solid Food and First Bowel Movement (GI2)

Time Frame: Up to 10 days After Surgery

Secondary Outcomes

  • Time From the End of Surgery to Time When the Discharge Order is Written(Up to 10 days After Surgery)
  • Percentage of Participants Requiring Postoperative Reinsertion of the Nasogastric Tube(Up to 10 days After Surgery)
  • Percentage of Participants With Nausea on Days 1 Through 3(Days 1 to 3 After Surgery)
  • Percentage of Participants With Vomiting on Days 1 Through 3(Days 1 to 3 After Surgery)
  • Percentage of Participants Discharged by Day 10 Who Are Readmitted for Any Reason Within 30 Days After Discharge From the Hospital(From the Discharge Date (Days 1-10) up to 30 Days After Discharge)

Investigators

Sponsor
Shionogi
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (8)

Loading locations...

Similar Trials